ADP and ATP analogues, process for making and administration to inhibit ADP-induced platelet aggregation
US5654285A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Jun 6, 1995 |
| Grant date | Aug 5, 1997 |
| Priority date | — |
| Expiry date | Jun 6, 2015 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07H19/20
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
There are disclosed compounds of formula I, ##STR1## wherein Q represents CR.sup.1 R.sup.2, R represents O or CR.sup.3 R.sup.4, W represents O or CH.sub.2, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently represent hydrogen or halogen, X represents S(O).sub.n R.sup.5, alkyl C.sub.1-6 alkoxy C.sub.1-6, acylamino C.sub.1-6, CONR.sup.6 R.sup.7, NR.sup.8 R.sup.9, halogen, a 5- or 6-membered S containing heterocycle, or phenyl optionally substituted by alkyl C.sub.1-6, n represents 0, 1 or 2, R.sup.5 represents aryl or alkyl C.sub.1-6 optionally substituted by one or more substituents selected from hydroxy, alkoxy C.sub.1-6, halogen and aryl; R.sup.6, R.sup.7, R.sup.8 and R.sup.9 independently represent hydrogen or alkyl C.sub.1-6, Y represents NH.sub.2 or alkoxy C.sub.1-6, and Z represents an acidic moiety, in addition, when R represents CR.sup.3 R.sup.4, then --Q--Z may also represent hydroxy or --OP(O)(OH).sub.2, and pharmaceutically acceptable salts thereof, with certain provisos, for use as pharmaceuticals.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.